反応式
O.Cl.[NH2:3][C@H:4]([C:7]([OH:9])=[O:8])[CH2:5][SH:6].[OH-].[K+].Cl.Cl[CH2:14][C:15]1[CH:24]=[CH:23][C:22]([OH:25])=[C:21]2[C:16]=1[CH:17]=[CH:18][CH:19]=[N:20]2.Cl.[K+].[Br-]>CS(C)=O.O>[OH:25][C:22]1[CH:23]=[CH:24][C:15]([CH2:14][S:6][CH2:5][C@@H:4]([C:7]([OH:9])=[O:8])[NH2:3])=[C:16]2[C:21]=1[N:20]=[CH:19][CH:18]=[CH:17]2参加物
反応物 5
生成物 1
試薬・触媒・溶媒 2
実験手順
L-cysteine hydrochloride hydrate (37 mg, 0.31 mmol) was dissolved in DMSO (3 ml). To the solution powdered KOH (36 mg, 0.34 mmol) was added, and the mixture was stirred for 30 min at room temperature. Then, powdered 5-chloromethyl-8-hydroxyquinoline hydrochloride (A2) (65 mg, 0.34 mmol) was added. The suspension was stirred at room temperature 12 h, 2 N HCl was added and the pH was adjusted to 5. The precipitate was washed with water and acetone. The crude product was further purified by semi-preparative HPLC to yield compound M12: 53 mg (61%). HPLC (tR): 38.1 min (linear gradient: 50% B for the first 4 min, increased linearly to 100% B for 60 min) [α]D20=+20.5° (c=1.0, H2O); 1H NMR (250 MHz, D2O) 2.89 (d, J=5.6 Hz, 2H), 3.95 (dd, J=5.1, 5.0 Hz,1H), 4.18 (s, 2H), 7.25 (d, J=8.0 Hz, 1H), 7.57 (d, J=8.0 Hz, 1H), 7.96 (dd, J=8.7, 5.5 Hz, 1H), 8.88 (d, J=5.4 Hz, 1H), 9.22 (d, J=8.7 Hz, 1H); IR (KBr) cm−1: 3438 (broad), 3081, 1685, 1637, 1560; Mass spectrometry: calculated for C12H12N2O3 m/z [M+H]+=279.33, found [M+H]+=279.13.
後処理
- additionwas added
- stirringThe suspension was stirred at room temperature 12 h
- washThe precipitate was washed with water and acetone
- customThe crude product was further purified by semi-preparative HPLC
- customto yield compound M12
出典と根拠
- ORDレコード
- ord-f895bd258ecf4ea5ba4ec27e3dd851f8
- 出典データセット
- uspto-grants-2011_11
- 特許番号
- US08058442B2
関連ノート
読み込み中…